Drug major Dr Reddy’s Laboratories Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with chronic kidney disease on dialysis, in the US market.
The newly launched product is in the strengths of 0.8 g and 2.4 g packets, and is a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.
Quoting IMS Health data, the company said the Renvela brand and generic had US sales of approximately USD 101 million for the most recent 12 months ending in October 2018.
Shares of Reddy’s Laboratories were trading 0.64 per cent lower at Rs 2,601.45 apiece on BSE.
